Simple SummaryA variety of MET aberrations that lead to the dysregulation of theMEToncogene and thus the activation of various signaling pathways have been described. These include MET overexpression, the activation ofMETmutations comprising exon 14 skipping mutations,METgene amplifications, andMETfusions. Patients with such aberrations can be treated using a targeted inhibitor such as crizotinib, cabozantinib, tepotinib, and capmatinib. Therefore, the implementation of high-quality and sensitive methods for the detection of the variousMETaberrations is essential.AbstractMET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in theMETproto-oncogene, including MET overexpression, the activation ofMETmutations,METmutations that lead toMETexon 14 skipping,METgene amplifications, andMETfusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all knownMETaberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the differentMETaberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics.